mTOR inhibitors were initiated for TSC-LAM at a mean (SD) age of 39.2 (11) years, a mean of five years earlier than those with sporadic LAM with a mean (SD) age of 44 (9) years (p = 0.009). Here, MTOR is linked to lymphangioleiomyomatosis.